Biotech Firm Clears Major U.S. Trading Hurdle
Source: Streetwise Reports  (7/18/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why. More >

Biotech Partnership to Revolutionize Diabetes Treatment
Source: Streetwise Reports  (7/15/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D). More >

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis  (7/14/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. More >

AI Healthtech Firm Partners with EngageWell and CVS Health Foundation on NYC Senior Care Initiative
Source: Streetwise Reports  (7/14/25)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launches virtual screening for older adults in NYC, backed by US$1M from CVS Health Foundation, as it scales AI tools and patient reach. Read more about how this initiative is helping expand access to care and driving growth in virtual health innovation. More >

Biopharma Firm Assembles Elite AI Cancer Team
Source: Streetwise Reports  (7/11/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) strengthens its AI-driven cancer program with a world-class advisory board and breakthrough drug discovery platforms. Read more about how Rakovina's expert-backed strategy and proprietary platforms support next-gen oncology drug development and potential licensing deals. More >

Canadian Biotech Targets Massive Cell Technology Gains
Source: Dr. Douglas Loe  (7/10/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently announced a partnership with Eledon Pharmaceuticals Inc. (ELDN:NASDAQ) to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy. More >

Biotech Firm Adjusts Placement Terms to Fuel U.S. Expansion
Source: Streetwise Reports  (7/7/25)
Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out. More >

Biotech Co. Still a Buy Despite Manufacturing Setbacks
Source: Emily Bodnar  (7/7/25)
While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note. More >

Vaccine Co. Secures European Regulatory Breakthrough Potential
Source: Dr. Jonathan Aschoff  (7/7/25)
GeoVax Labs Inc. (GOVX:NASDAQ) recently raised US$6 million, projected to find operations through the last quarter of 2025, according to a ROTH Capital Markets research note. The company also received highly favorable guidance for GEO-MVA, its prophylactic vaccine for Mpox and smallpox from The European Medicines Agency. More >

Biotech Company Finds DNA-Targeting Drugs with AI in Canada
Source: Streetwise Reports  (7/2/25)
Biopharmaceutical company Rakovina Therapeutics Inc. (RKV:TSX.V) shared AGM results and key AI-driven cancer drug milestones in Vancouver. Read why some analysts are seeing a 300% potential return More >

Analyst Has Confidence in Biotech's Path
Source: Dr. Joseph Pantginis  (6/26/25)
Vertex Pharmaceuticals Inc.'s (VRTX:NASDAQ) updated data is "a strong positive read-through for Sernova and help de-risk the broader field of cell-based therapies in T1D," according to an H.C. Wainwright & Co. research note. More >

Isotope Co. Discovers Uranium-Helium Breakthrough Potential
Source: Streetwise Reports  (6/24/25)
ASP Isotopes Inc. (ASPI:NASDAQ) is seeing at least two major transformative developments this month. Read why one analyst sees these events as positive. More >

Sirens of High Finance
Source: Michael Ballanger  (6/23/25)
Michael Ballanger of GGM Advisory Inc. shares his take on the current state of the market and reviews one copper stock he has been betting on for a while. More >

California Biotech's Trial Shows Encouraging Results
Source: Dr. Joseph Pantginis  (6/20/25)
Kura Oncology Inc.'s (KURA:NASDAQ) KOMET-007 trial results, supporting ziftomenib's benefit-risk profile for first-line acute myeloid leukemia, were encouraging, according to an H.C. Wainwright & Co. research note. More >

Orogen: End of Another Chapter Draws Near
Source: Adrian Day  (6/16/25)
Global Analyst Adrian Day discusses developments at some companies on his list, including Orogen Royalties Inc. (OGN:TSXV; OGNRF:OTCQX) and Franco-Nevada Corp. (FNV:TSX; FNV:NYSE). More >

Q1/25 Financials of Cancer Drug Developer Released
Source: Dr. Douglas Loe  (6/12/25)
Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report. More >

Biotech Firm Unveils Diabetes Breakthrough in Canada
Source: Streetwise Reports  (6/10/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes. More >

New RA Drug Shown to Work, Be Safe
Source: Dr. Martin Fan  (6/10/25)
"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report. More >

Analyst Likes Co. Developing Immuno-oncology Drugs
Source: Dr. Matthew Keller  (6/10/25)
There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report. More >

Co.'s New Cancer Drug Shows Promise
Source: Jason Kolbert  (6/9/25)
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report. More >

Biotech Co. Reaches MS Clinical Program Milestones
Source: Jason Kolbert  (6/9/25)
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report. More >

Phase 2b Trial Data on Treatment for Inflammation Due Soon
Source: Dr. Jonathan Aschoff  (6/9/25)
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report. More >

Canadian Biotech Advances High-Impact DDR Programs
Source: Streetwise Reports  (6/6/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) secures CA$4M in strategic funding, boosts AI-powered cancer programs, and eyes 300% potential return with DDR breakthroughs. Read more about the companys scientific momentum, analyst coverage, and AI-driven oncology strategy. More >

Biotech Company Unlocks Gene Therapy Breakthrough in Canada
Source: Streetwise Reports  (6/6/25)
PreveCeutical Preventive Health Sciences (PREV:CSE; PRVCF:OTC; 18H:FSE) moves gene and pain therapy assets into new entities in Canada, with proof-of-concept studies signaling major delivery breakthroughs. Find out how the company's strategy to form independent entities and leverage proprietary delivery platforms is positioning it for growth across multiple therapeutic markets.

More >

Data Readout Positive from Trial of New Schizophrenia Drug
Source: Jason Kolbert  (6/4/25)
This new dopamine-serotonin system modulator showed sustained efficacy over 52 weeks and a favorable tolerability and safety profile, noted a D. Boral Capital report. More >